Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02158520
Title Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Saint Mary's Medical Center San Francisco California 94117 United States Details
Mayo Clinic in Florida Jacksonville Florida 32224-9980 United States Details
University of Illinois Chicago Illinois 60612 United States Details
University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa 52242 United States Details
Siouxland Regional Cancer Center Sioux City Iowa 51101 United States Details
Cancer Research Consortium of West Michigan NCORP Grand Rapids Michigan 49503 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Metro Minnesota Community Oncology Research Consortium Saint Louis Park Minnesota 55416 United States Details
Missouri Valley Cancer Consortium Omaha Nebraska 68106 United States Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
Saint Vincent Hospital Cancer Center Green Bay Green Bay Wisconsin 54301 United States Details
University of Wisconsin Hospital and Clinics Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field